306 related articles for article (PubMed ID: 38829443)
1. Targeting Biometals in Alzheimer's Disease with Metal Chelating Agents Including Coumarin Derivatives.
Gucký A; Hamuľaková S
CNS Drugs; 2024 Jul; 38(7):507-532. PubMed ID: 38829443
[TBL] [Abstract][Full Text] [Related]
2. Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives.
Fasae KD; Abolaji AO; Faloye TR; Odunsi AY; Oyetayo BO; Enya JI; Rotimi JA; Akinyemi RO; Whitworth AJ; Aschner M
J Trace Elem Med Biol; 2021 Sep; 67():126779. PubMed ID: 34034029
[TBL] [Abstract][Full Text] [Related]
3. Management of oxidative stress and other pathologies in Alzheimer's disease.
Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
Huang M; Xie SS; Jiang N; Lan JS; Kong LY; Wang XB
Bioorg Med Chem Lett; 2015 Feb; 25(3):508-13. PubMed ID: 25542589
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine-Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases.
Vicente-Zurdo D; Brunetti L; Piemontese L; Guedes B; Cardoso SM; Chavarria D; Borges F; Madrid Y; Chaves S; Santos MA
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176018
[TBL] [Abstract][Full Text] [Related]
6. Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity.
Chaves S; Várnagy K; Santos MA
Curr Med Chem; 2021; 28(35):7247-7277. PubMed ID: 33602068
[TBL] [Abstract][Full Text] [Related]
7. Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer's disease therapy.
Youdim MBH
J Neural Transm (Vienna); 2022 Jun; 129(5-6):715-721. PubMed ID: 35190910
[TBL] [Abstract][Full Text] [Related]
8. Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Yang X; Qiang X; Li Y; Luo L; Xu R; Zheng Y; Cao Z; Tan Z; Deng Y
Bioorg Chem; 2017 Apr; 71():305-314. PubMed ID: 28267984
[TBL] [Abstract][Full Text] [Related]
9. Dual-target anti-Alzheimer's disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity.
Mi Z; Gan B; Yu S; Guo J; Zhang C; Jiang X; Zhou T; Su J; Bai R; Xie Y
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1489-1497. PubMed ID: 31416364
[TBL] [Abstract][Full Text] [Related]
10. New 4-N-phenylaminoquinoline derivatives as antioxidant, metal chelating and cholinesterase inhibitors for Alzheimer's disease.
Cai R; Wang LN; Fan JJ; Geng SQ; Liu YM
Bioorg Chem; 2019 Dec; 93():103328. PubMed ID: 31600664
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
Xie S; Chen J; Li X; Su T; Wang Y; Wang Z; Huang L; Li X
Bioorg Med Chem; 2015 Jul; 23(13):3722-9. PubMed ID: 25934229
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
Joubert J; Foka GB; Repsold BP; Oliver DW; Kapp E; Malan SF
Eur J Med Chem; 2017 Jan; 125():853-864. PubMed ID: 27744252
[TBL] [Abstract][Full Text] [Related]
13. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
14. Rebalancing metal dyshomeostasis for Alzheimer's disease therapy.
Yang GJ; Liu H; Ma DL; Leung CH
J Biol Inorg Chem; 2019 Dec; 24(8):1159-1170. PubMed ID: 31486954
[TBL] [Abstract][Full Text] [Related]
15. Metal Ions in Alzheimer's Disease: A Key Role or Not?
Liu Y; Nguyen M; Robert A; Meunier B
Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
[TBL] [Abstract][Full Text] [Related]
16. Polyphenols as Potential Metal Chelation Compounds Against Alzheimer's Disease.
Lakey-Beitia J; Burillo AM; La Penna G; Hegde ML; Rao KS
J Alzheimers Dis; 2021; 82(s1):S335-S357. PubMed ID: 32568200
[TBL] [Abstract][Full Text] [Related]
17. Coumarins: Auspicious Cholinesterase and Monoamine Oxidase Inhibitors.
Orhan IE; Gulcan HO
Curr Top Med Chem; 2015; 15(17):1673-82. PubMed ID: 25915613
[TBL] [Abstract][Full Text] [Related]
18. Challenges and Opportunities of Metal Chelation Therapy in Trace Metals Overload-Induced Alzheimer's Disease.
Chaudhari V; Bagwe-Parab S; Buttar HS; Gupta S; Vora A; Kaur G
Neurotox Res; 2023 Jun; 41(3):270-287. PubMed ID: 36705861
[TBL] [Abstract][Full Text] [Related]
19. Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents.
Xu Y; Zhang J; Wang H; Mao F; Bao K; Liu W; Zhu J; Li X; Zhang H; Li J
ACS Chem Neurosci; 2019 Jan; 10(1):482-496. PubMed ID: 30110536
[TBL] [Abstract][Full Text] [Related]
20. The impact of chelating compounds on Cu
Mazur T; Malik M; Bieńko DC
J Inorg Biochem; 2024 Aug; 257():112601. PubMed ID: 38744143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
